SPDR S&P Biotech ETF (XBI)
|Ex-Dividend Date||Mar 22, 2021|
|Day's Range||121.96 - 124.23|
|Inception Date||Jan 31, 2006|
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
Top 10 Holdings9.89% of assets
|Global Blood Therapeutics||GBT||0.86%|
|Mar 22, 2021||$0.040||Mar 25, 2021|
|Dec 21, 2020||$0.176||Dec 24, 2020|
|Sep 21, 2020||$0.08897||Sep 24, 2020|
|Jun 22, 2020||$0.01676||Jun 25, 2020|
|Dec 20, 2019||$0.00086||Dec 26, 2019|
|Sep 20, 2019||$0.00319||Sep 25, 2019|
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Is the biotech sell-off a buying opportunity
Jared Holz, Oppenheimer, on whether the dip in biotech is an opportunity for investors. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Jeff Mills.
MPM's Bardon on biotech investing outlook, $850 million oncology fund
Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins CNBC's 'Squawk Box' to discuss the public and private biotech investing landscape.
The S&P 500 has been in a great shape this year, calling for overvaluation concerns. Why not investing in ETFs that have underperformed the S&P 500, have a lower P/E and have a Buy rating.
Biotech ETFs shot higher after the FDA formally approved Pfizer's vaccine. Trade the group's two largest funds with these tactical ideas.
While the world's leading biotech companies — churning out Covid-19 vaccines and treatments — have hit record share prices, their.
The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out. Resistance is a large group of sellers who are...
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.